New Investing App Saves Investors an Average of $97,347
Most people are terrible at buying and selling stocks at the right time, but the TradeSmith app takes the emotion out of investing.

Our back test shows, the average investor would've made $97,347 more just by using the TradeSmith app analyzer software.

Check out this FREE video.
>>>
Alexander Edward Kuta, III, insider at uniQure

Alexander Edward Kuta, III Insider Information

VP of uniQure
Dr. Alex Kuta joined uniQure in January 2017 as Senior Vice President, Regulatory Affairs. In his current role as Executive Vice President, Operations, he is responsible for global quality and regulatory affairs, as well as GMP manufacturing at uniQure’s state-of-the-art facility in Lexington, Massachusetts. 

He joined uniQure from EMD Serono, where he served as Vice President of Research & Development Global Regulatory Affairs and where he was a member of the U.S. Leadership Team.  In this role, he was responsible for driving the strategic direction of EMD Serono’s regulatory efforts in immune-mediated diseases, oncology and regulatory CMC, as well as strengthening interactions with the U.S. Food and Drug Administration (FDA).

Prior to joining EMD Serono, Dr. Kuta was Vice President of Global Regulatory Affairs and a member of the Executive Leadership Team at Lantheus Medical Imaging. His previous experience includes senior roles at AMAG Pharmaceuticals and at Genzyme Corporation, where he served for 15 years in regulatory leadership positions of increasing responsibility.  Prior to joining industry, he was Chief of the Cytokine and Gene Therapy Branch in the Center for Biologics at FDA.   Dr. Kuta has also served as a member of the BIO Regulatory Affairs Leadership Committee, Cell and Gene Therapy Working Group and the ICH Gene Therapy Working Group.

Dr. Kuta holds a Bachelor of Science degree from Saint John's University and a Ph.D. from Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his post-doctoral studies at the National Cancer Institute/ National Institutes of Health.

What is Alexander Edward Kuta, III's net worth?

The estimated net worth of Alexander Edward Kuta, III is at least $1.38 million as of July 15th, 2021. Dr. Kuta, III owns 74,871 shares of uniQure stock worth more than $1,382,867 as of June 30th. This net worth evaluation does not reflect any other assets that Dr. Kuta, III may own. Learn More about Alexander Edward Kuta, III's net worth.

How do I contact Alexander Edward Kuta, III?

The corporate mailing address for Dr. Kuta, III and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at [email protected] Learn More on Alexander Edward Kuta, III's contact information.

Has Alexander Edward Kuta, III been buying or selling shares of uniQure?

Alexander Edward Kuta, III has not been actively trading shares of uniQure over the course of the past ninety days. As far as recent transactions, on Thursday, June 30th, 0 shares of BMO Capital Markets stock. Learn More on Alexander Edward Kuta, III's trading history.

Who are uniQure's active insiders?

uniQure's insider roster includes Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Christian Klemt (CFO), and Alexander Kuta, III (VP). Learn More on uniQure's active insiders.

Are insiders buying or selling shares of uniQure?

In the last twelve months, insiders at the biotechnology company sold shares 22 times. They sold a total of 104,105 shares worth more than $2,601,492.71. The most recent insider tranaction occured on June, 16th when COO Pierre Caloz sold 7,575 shares worth more than $100,065.75. Insiders at uniQure own 2.7 % of the company. Learn More about insider trades at uniQure.

Information on this page was last updated on 6/16/2022.

Alexander Edward Kuta, III Insider Trading History at uniQure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2022Sell3,405$16.72$56,931.60View SEC Filing Icon  
1/26/2022Sell2,945$18.02$53,068.90View SEC Filing Icon  
12/15/2021Sell6,000$27.90$167,400.00View SEC Filing Icon  
11/15/2021Sell6,000$31.81$190,860.00View SEC Filing Icon  
10/15/2021Sell6,000$30.65$183,900.00View SEC Filing Icon  
9/21/2021Sell2,229$36.71$81,826.59View SEC Filing Icon  
9/15/2021Sell6,000$36.32$217,920.00View SEC Filing Icon  
8/16/2021Sell6,000$28.84$173,040.00View SEC Filing Icon  
7/15/2021Sell6,000$27.22$163,320.0074,871View SEC Filing Icon  
6/15/2021Sell6,000$35.43$212,580.0074,871View SEC Filing Icon  
5/17/2021Sell6,000$31.66$189,960.0074,871View SEC Filing Icon  
4/15/2021Sell6,000$35.06$210,360.0074,871View SEC Filing Icon  
1/26/2021Sell713$39.01$27,814.1356,147View SEC Filing Icon  
9/18/2020Sell2,230$41.18$91,831.4056,860View SEC Filing Icon  
1/28/2020Sell1,478$62.14$91,842.9241,569View SEC Filing Icon  
1/15/2020Sell4,000$68.97$275,880.0045,578View SEC Filing Icon  
12/16/2019Sell4,000$74.59$298,360.0045,578View SEC Filing Icon  
11/15/2019Sell4,000$52.08$208,320.0045,578View SEC Filing Icon  
10/15/2019Sell4,000$42.35$169,400.0045,578View SEC Filing Icon  
9/16/2019Sell4,000$47.26$189,040.0030,578View SEC Filing Icon  
2/15/2019Sell8,000$35.82$286,560.00View SEC Filing Icon  
1/28/2019Sell1,052$31.29$32,917.0826,578View SEC Filing Icon  
See Full Table

Alexander Edward Kuta, III Buying and Selling Activity at uniQure

This chart shows Alexander Edward Kuta III's buying and selling at uniQure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

uniQure Company Overview

uniQure logo
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $18.52
Low: $18.00
High: $18.60

50 Day Range

MA: $15.05
Low: $13.15
High: $19.54

2 Week Range

Now: $18.52
Low: $12.52
High: $38.80

Volume

7,386 shs

Average Volume

585,617 shs

Market Capitalization

$863.92 million

P/E Ratio

2.65

Dividend Yield

N/A

Beta

1.13
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.